USE OF GLP-1 RECEPTOR AGONISTS IN THE TREATMENT OF OBESITY: CLINICAL EVIDENCE AND NUTRITIONAL IMPLICATIONS
DOI:
https://doi.org/10.61164/dgpn4685Keywords:
GLP-1 Receptor Agonists, Obesity, Semaglutide, Tirzepatide, Nutritional deficienciesAbstract
Obesity is a chronic condition that is difficult to manage, requiring therapeutic strategies that go beyond invasive interventions. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists (GIP/GLP-1) has established a new paradigm in the pharmacological treatment of obesity, achieving weight loss ranging from 15% to 30%, which, in certain contexts, is comparable to outcomes observed after bariatric surgery. This study aimed to analyze the efficacy and metabolic impacts of semaglutide and tirzepatide, with an emphasis on challenges related to therapeutic adherence and clinical safety. This is a literature review, which indicates that despite high clinical efficacy, the use of these medications is associated with frequent gastrointestinal adverse effects, such as nausea and constipation, as well as relevant risks of nutritional deficiencies, particularly in the absence of adequate monitoring. The most commonly reported deficiencies include minerals such as iron, calcium, and magnesium, as well as B-complex vitamins and fat-soluble vitamins (A, D, E, and K). It is concluded that therapeutic success depends on a multidisciplinary approach integrating pharmacotherapy with nutritional monitoring and regular physical exercise, aiming to preserve lean mass and ensure the long-term sustainability of caloric deficit.
Downloads
References
ARLOTA, A. et al. Efeitos da semaglutida na perda de gordura e de massa muscular. Brazilian Journal of Implantology and Health Sciences, [s. l.], v. 6, n. 2, p. 2018–2035, 2024. DOI: https://doi.org/10.36557/2674-8169.2024v6n2p2018-2035
ASSOCIAÇÃO BRASILEIRA PARA O ESTUDO DA OBESIDADE E DA SÍNDROME METABÓLICA (ABESO). Diretrizes brasileiras de obesidade 2016. 4. ed. São Paulo: ABESO, 2016.
BRASIL. Ministério da Saúde. Ministério da Saúde lança publicação sobre indicadores de prática de atividades físicas entre os brasileiros. Brasília, DF, 2022. Disponível em: https://www.gov.br/saude/pt-br/assuntos/noticias/2022/agosto/ministerio-da-saude-lanca-publicacao-sobre-indicadores-de-pratica-de-atividades-fisicas-entre-os-brasileiros. Acesso em: 13 dez. 2025.
BRASIL. Ministério da Saúde. Vigitel Brasil 2006–2021: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico. Brasília, DF: Ministério da Saúde, 2021.
HALPERN, B.; MANCINI, M. C. Tratado de obesidade. 4. ed. Rio de Janeiro: Guanabara Koogan, 2024.
JASTREBOFF, A. M. et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, v. 387, n. 3, p. 205–216, 4 jun. 2022. DOI: https://doi.org/10.1056/NEJMoa2206038
MOZAFFARIAN, D. et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition, v. 122, n. 1, 30 maio 2025.
NEPOMUCENO, G. da C.; PEREIRA, A. da S.; SIMÕES, B. F. T. Padrões alimentares e sua relação com doenças crônicas não transmissíveis ao longo do tempo. Ciência & Saúde Coletiva, v. 30, n. 5, maio 2025. DOI: https://doi.org/10.1590/1413-81232025305.16662023
RUBIO-HERRERA, M. A.; MERA-CARREIRO, S. Weight management treatment in obesity. Medicina Clínica, v. 165, n. 5, p. 107152–107152, 26 ago. 2025. DOI: https://doi.org/10.1016/j.medcli.2025.107152
SOCIEDADE BRASILEIRA DE CIRURGIA BARIÁTRICA E METABÓLICA (SBCBM). História da cirurgia bariátrica no Brasil. São Paulo, 2015. Disponível em: https://www.sbcbm.org.br. Acesso em: 13 dez. 2025.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Vanessa Amorim Martins, Jullyan Silva Goes Estevam de Godoy, Mateus de Lima Macena, André Eduardo Silva Júnior

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
